Perrigo Company plc last reported quarterly results on Nov 4, 2026, for Q3 FY2026 (the quarter ended Sep 26, 2026): revenue of $988.6 million (-5.2% year over year) and diluted EPS of -$0.20. It usually reports 25–57 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 25, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Feb 26, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 25–57 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
39 days after quarter end
|
Q3 FY2026
ended Sep 26, 2026
|
989
-5.2%
|
-28
-466.7%
|
-0.20
-500.0%
|
|
Aug 5, 2026
39 days after quarter end
|
Q2 FY2026
ended Jun 27, 2026
|
1,023
-3.2%
|
74
+986.9%
|
0.53
+983.3%
|
|
Apr 22, 2026
25 days after quarter end
|
Q1 FY2026
ended Mar 28, 2026
|
969
-7.2%
|
-399
-6128.1%
|
-2.87
-5640.0%
|
|
Feb 26, 2026
57 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
1,110
-2.5%
|
-1,418
-3086.7%
|
-10.30
-3087.6%
|
|
Nov 5, 2025
39 days after quarter end
|
Q3 FY2025
ended Sep 27, 2025
|
1,043
-4.1%
|
8
+135.7%
|
0.05
+133.3%
|
|
Aug 6, 2025
39 days after quarter end
|
Q2 FY2025
ended Jun 28, 2025
|
1,056
-0.9%
|
-8
+92.3%
|
-0.06
+92.4%
|
|
May 7, 2025
39 days after quarter end
|
Q1 FY2025
ended Mar 29, 2025
|
1,044
-3.5%
|
-6
-420.0%
|
-0.05
-600.0%
|
|
Feb 27, 2025
58 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
1,138
-1.6%
|
-44
-37.8%
|
-0.32
-31.5%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PRGO (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- Ireland
- Headquarters
- Dublin 2, Ireland
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1585364
- Former names
- PERRIGO Co Ltd (until Nov 12, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.